A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ischemic stroke on top of its older approval in acute ST-elevation myocardial infarction. Tenecteplase ...

Patients with acute stroke benefit from thrombolysis with IV tissue plasminogen activator (tPA). In the last decade, a number of endovascular techniques have increasingly been used to open blood ...

TNKase was initially approved in 2000 to reduce the risk of death from acute ST-elevation myocardial infarction (STEMI ... of a natural protein called tPA, which helps break down blood clots.

All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.